Olorinab

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
Olorinab
Olorinab structure.png
Clinical data
Routes of
administration
Oral
Identifiers
CAS Number
PubChem CID
KEGG
Chemical and physical data
FormulaC18H24N5O3
Molar mass358.414 g/mol g·mol−1
3D model (JSmol)

Olorinab (APD371) is a drug developed by Arena Pharmaceuticals for the treatment of Gastrointestinal pain associated with Crohn's disease and Irritable Bowel Syndrome.[1] It acts as a potent and selective cannabinoid CB2 receptor agonist and is claimed to be orally active and peripherally selective.[2][3] Initial Phase IIa exploratory clinical trials have been successful,[4] with Phase IIb trials projected to start in 2019.[5]

See also[edit]

References[edit]

  1. ^ "Arena Pharmaceuticals Presented New Phase 2 Data for Etrasimod and Olorinab at the 14th Congress of European Crohn's and Colitis Organisation". Arena Pharmaceuticals, Inc. Retrieved 2019-04-13.
  2. ^ Han S, Thoresen L, Jung JK, Zhu X, Thatte J, Solomon M, et al. (December 2017). "Discovery of APD371: Identification of a Highly Potent and Selective CB2 Agonist for the Treatment of Chronic Pain". ACS Medicinal Chemistry Letters. 8 (12): 1309–1313. doi:10.1021/acsmedchemlett.7b00396. PMID 29259753.
  3. ^ "Olorinab (APD371)". Arena Pharmaceuticals, Inc.
  4. ^ "Arena Pharmaceuticals Reports Positive Phase 2a Results for Olorinab in Patients with Abdominal Pain Associated with Crohn's Disease". Arena Pharmaceuticals, Inc. Retrieved 2019-04-13.
  5. ^ "18th Annual Needham Healthcare Conference". wsw.com. Retrieved 2019-04-13.